Vaccination for seasonal influenza in patients with cancer: Recommendations of the Italian Society of Medical Oncology (AIOM)

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1243-1247

  Pedrazzoli, Paolo ^a   Baldanti, F ^a   Donatelli, I ^b   Castrucci, M R ^b   Puglisi, F ^c   Silvestris, N ^d   Cinieri, S ^e  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e Division of Medical Oncology   (Italy)

Author keywords

Cancer; Influenza; Vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC AGENT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OSELTAMIVIR; RITUXIMAB; SORAFENIB; SUNITINIB; ZANAMIVIR;

ALLERGIC REACTION; ANTIBODY RESPONSE; ARTHROMYALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG MEGADOSE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; ITALY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MYALGIA; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SOLID TUMOR; INFLUENZA, HUMAN; NEOPLASM; PROCEDURES; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEOPLASMS; VACCINATION;

EID: 84903884135     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu114     Document Type: Article

References (33)

1. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197-201.
2. Campanini G, Piralla A, Paolucci S et al. Genetic divergence of influenza A NS1 gene in pandemic 2009 H1N1 isolates with respect to H1N1 and H3N2 isolates from previous seasonal epidemics. Virol J 2010; 7: 209.
3. Cooksley CD, Avritscher EB, Bekele BN et al. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104: 618-628.
4. Meerveld-Eggink A, de Weerdt O, van der Velden AM et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol 2011; 22: 2031-2035.
5. Ison MG, Hui DS, Clezy K et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2012; 18: 651-661.
6. Nelson KE. Influenza vaccine and Guillain-Barre syndrome-is there a risk? Am J Epidemiol 2012; 175: 1129-1132.
7. Boehmer LM, Waqar SN, Govindan R. Influenza vaccination in patients with cancer: an overview. Oncology 2010; 24: 1167-1170.
8. Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2013; 8: CD006484. doi: 10.1002/14651858.CD006484.pub3.
9. Rapezzi D, Sticchi L, Racchi O et al. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003; 70: 225-230.
10. Centkowski P, Brydak L, Machala M et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymhoma. J Clin Immunol 2007; 27: 339-346.
11. Beck CR, McKenzie BC, Hashim AB et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by aetiology. J Infect Dis 2012; 206: 1250-1259.
12. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978; 42: 2244-2247.
13. Anderson H, Petrie K, Berrisford C et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999; 80: 219-220.
14. Ring A, Marx G, Steer C et al. Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer 2002; 10: 462-465.
15. Ortbals DW, Liebhaber H, Presant CA et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977; 87: 552-557.
16. Mackay HJ, McGee J, Villa D et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011; 50: 212-216.
17. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010; 28: 2481-2490.
18. Gross PA, Lee H, WolffJA et al. Influenza immunization in immunosuppressed children. J Pediatr 1978; 92: 30-35.
19. Steinherz PG, Brown AE, Gross PA et al. Influenza immunization of children with neoplastic diseases. Cancer 1980; 45: 750-756.
20. Matsuzaki A, Suminoe A, Koga Y et al. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005; 45: 831-837.
21. Bedognetti D, Zoppoli G, Massucco C et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011; 186: 6044-6055.
22. Hottinger AF, George AC, Bel M et al. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist 2012; 17: 436-445.
23. Issa NC, Marty FM, Gagne LS et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 434-438.
24. Yri OE, Torfoss D, Hungnes O et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118: 6769-6771.
25. Bedognetti D, Ansaldi F, Zanardi E et al. Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood 2012; 120: 1954-1957.
26. Rousseau B, Loulergue P, Mir O et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 2012; 23: 450-457.
27. Mulder SF, Jacobs JF, Olde Nordkamp MA et al. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res 2011; 17: 4541-4549.
28. Kroon FP, van Dissel JT, de Jong JC et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18: 3040-3049.
29. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomized study. Br J. Haematol 2005; 130: 96-98.
30. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11: 415-427.
31. Jo YM, Song JY, Hwang IS et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009; 81: 722-727.
32. Campanini G, Piralla A, Rovida F et al. Surveillance Group for New Influenza A/H1N1v Investigation in Italy. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J Clin Virol 2010; 48: 220-222.
33. Esposito S, Molteni CG, Colombo C et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol 2010; 48: 62-65.